TARA

2.2805.00%
LM

Luke M. Beshar

Independent Chairman of the Board

Mr. Luke M. Beshar, CPA, M.B.A. is Independent Chair of Quell Therapeutics Ltd from July 2024. He serves as Chairman of the Board at Proteon Therapeutics Inc. (formerly, Protara Therapeutics, Inc. and ArTara Therapeutics, Inc.) since January 2020 and has been its Director since October 2018. Mr. Beshar serves as the Chairman of the Board at Inotrem S.A. He has been a Director of PNY Technologies, Inc. since December 31, 2003. He served as Independent Director at Omega Therapeutics, Inc. since May 2021 until June 20, 2024. Mr. Beshar served as an Independent Director of Trillium Therapeutics Inc. since March 10, 2014 until November 17, 2021. He served as Independent Director at Regenxbio Inc. since April 25, 2015 until September 3, 2021. He was Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals, Inc. from November 2007 to February 2015. He served as a Senior Vice President of NPS Pharmaceuticals, Inc. from November 20, 2007 to January 1, 2012. Mr. Beshar is an independent biotechnology consultant and financial expert. He identified and evaluated strategic and corporate development opportunities, lead investor relations, assist in the establishment of the new line of credit, oversee transition services provided to the buyers of the divested businesses and direct other special projects. He served as Executive Vice President of Finance and Chief Financial Officer at Netexit, Inc. He served as the Chief Financial Officer and Executive Vice President of Cambrex Corporation from December 5, 2002 to November 2007, its Executive Vice President of Corporate Development and Strategy from February 9, 2007 to October 1, 2007, its Senior Vice President since December 5, 2002, its Executive Vice President since January 2004 and also served as its Principal Accounting Officer. He began his career with Arthur Andersen & Co. in 1980. From January 2002 to December 2002, Mr. Beshar served as Senior Vice President and Chief Financial Officer of Cegedim Inc. He served as an Executive Vice President of Finance and Chief Financial Officer for Expanets, Inc. from November 1998 to January 2002 and as Executive Vice President and Chief Financial Officer of PNY Technologies, Inc. from 1996 to 1998. He served as the Chief Financial Officer of Dendrite International, WSR Corporation, The Genlyte Group, Inc. and Bairnco Corporation. He was instrumental in upgrading the corporate and business unit financial staffs. He directed the evaluation of strategic alternatives, a yearlong, corporate-wide effort resulting in the recent sale of the Bioproducts and Biopharma businesses. He served as the Chairman of The Board at Entera Bio Ltd. from December 2016 to June 30, 2018. He is a Member of the New York Society of Certified Public Accountants. Mr. Beshar earned his B.A. in Accounting and Financial Administration from Michigan State University and is a graduate of the Executive Program of the Darden Graduate Business School at the University of Virginia.

Positions